Synthesis and initial evaluation of [11C](R)-RWAY in monkey—a new, simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET
- 125 Downloads
We aimed to fulfill a need for a radioligand that may be simply labeled with carbon-11 for effective positron emission tomography (PET) imaging of brain 5-HT1A receptors.
Racemic RWAY (2,3,4,5,6,7-hexahydro-1-[4-[1-[4-(2-methoxyphenyl)piperazinyl]]-2-phenylbutyryl]-1H-azepine) has high affinity for 5-HT1A receptors. The enantiomers of RWAY and O-desmethyl-RWAY, synthesized from commercially available materials, were each labeled with carbon-11 by treating the respective O-desmethyl precursor with [11C]iodomethane, and injected into rhesus monkey for measurement of regional brain uptake. The 5-HT1A selectivity of (R)-[11C]RWAY was checked by administering WAY-100635, before and after radioligand administration. Radiometabolites of (R)-[11C]RWAY in blood and urine were analyzed by HPLC with partial elucidation of their structures by LC-MS-MS.
(R)-[11C]RWAY was a 5-HT1A receptor antagonist exhibiting high brain uptake with regional distribution consistent with specific binding to 5-HT1A receptors. The similar affinity, (S)-[11C]RWAY was a weak partial agonist at 5-HT1A receptors exhibiting similar brain peak uptake with much less 5-HT1A receptor-specific binding. The maximal ratio in receptor-rich cingulate gyrus to receptor-devoid cerebellum reached 6.4 at 87.5 min after injection of (R)-[11C]RWAY. After treatment with WAY-100635 before or after (R)-[11C]RWAY administration, radioactivity levels in 5-HT1A receptor-rich regions were reduced almost to that in cerebellum. Blood and urine radiometabolites were less lipophilic than parent and were not due to hydrolysis but to ring hydroxylations, oxidation, and dephenylation.
(R)-[11C]RWAY is simply prepared and an effective antagonist for imaging brain 5-HT1A receptors. This radioligand resists hydrolysis in vivo, gives less lipophilic radiometabolites, and warrants further PET studies in human subjects.
Keywords5-HT1A receptor PET Radioligand [11C](R)-RWAY Imaging
This work was supported by the Intramural Research Program of the National Institutes of Health (National Institute of Mental Health; project # Z01-MH-002852-01). An early phase of this project was also supported by the Human Frontier Science Program Organization (grant # RG 235/98). We are grateful to the National Institute of Mental Health Psychoactive Drug Screening Program (Director Dr. Bryan L. Roth) for performing binding and functional assays, and to Mr Jinsoo Hong for assistance in radioligand production.
- 1.Pike VW, McCarron JA, Hume SP, Ashworth S, Opacka-Juffry J, Osman S, et al. Pre-clinical development of a radioligand for studies of central 5-HT1A receptors in vivo—[11C]WAY-100635. Med Chem Res 1994;5:208–27.Google Scholar
- 6.Osman S, Lundkvist C, Pike VW, Halldin C, McCarron JA, Swahn CG, et al. Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl Med Biol 1996;23:627–34.PubMedCrossRefGoogle Scholar
- 7.Osman S, Lundkvist C, Pike VW, Halldin C, McCarron JA, Swahn CG, et al. Characterization of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635—explanation of high signal contrast in PET and an aid to biomathematical modeling. Nucl Med Biol 1998;25:215–23.PubMedCrossRefGoogle Scholar
- 13.Itsenko O, Kihlberg T, Blom E, Långström B. One step synthesis of [carbonyl- 11C]WAY-100635. J Label Compd Radiopharm 2005:48;S135.Google Scholar
- 14.Carson RE, Toczek MT, Lang LX, Fraser C, Spanaki MV, Ma Y, et al. Human functional imaging with the 5-HT1A ligand 18F-FCWAY. J Nucl Med 2002;198(Suppl S):55P.Google Scholar
- 20.Cliffe IA. Piperazine derivatives. EP 481744 A1, 1991.Google Scholar
- 21.Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, et al. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem 2003;46:3822–39.PubMedCrossRefGoogle Scholar
- 23.Zoghbi SS, Baldwin RM, Seibyl J, Charney DS, Innis RB. A radiotracer technique for determining apparent pKa of receptor binding ligands. J Label Compd Radiopharm 1997;42:S136–8.Google Scholar
- 24.Clark JD, Baldwin RL, Bayne KA, Brown MJ, Gebhart GF, Gunder JC, et al. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996.Google Scholar
- 26.Shepherd RG. Process for the preparation of o-aryl-γ-butyrolactones. WO 94/12487. 1994.Google Scholar
- 27.Shuomingshu FZSG. Preparation of the known neurotransmitter antagonist 1-[4-[4-(methoxyphenyl)-1-piperazinyl]-4-phenylbutyryl]hexahydro-1H-azepine and its salts and enantiomers. CN 10766446. 1993.Google Scholar
- 28.Ashwell MA. Amide derivatives. WO 9408983.1994.Google Scholar